Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

aTYR PHARMA INC (ATYR)

$0.47 -4.98% NASDAQ: ATYR · 15-min delayed
  • SAN DIEGO, California
  • Public · NASDAQ: ATYR
  • 58 employees
$46.1MMarket cap
$190.0KRevenue · FY2025
-$74.1MNet income
58Employees
ATYRNASDAQ
2015IPO

About aTYR PHARMA INC

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$190.0K
Net income
-$74.1M
Total assets
$93.0M
Market cap
$46.1M
Operating margin
-40856.3%
Net margin
-39012.1%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$190.0K
Operating expenses
$77.8M
Operating income
-$77.6M
Income tax
$0
Net income
-$74.1M
EPS (basic)
$-0.80
EPS (diluted)
$-0.80

Balance sheet

Total assets
$93.0M
Current assets
$80.2M
Total liabilities
$25.7M
Current liabilities
$15.1M
Shareholders’ equity
$67.3M

Cash flow

Operating cash flow
-$62.0M
Investing cash flow
-$5.1M
Financing cash flow
$66.0M
Net cash flow
-$1.0M

Statements via Polygon.io (SEC filings)

NASDAQ: ATYR
$0.47 -4.98%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.40 $6.61

52-week range

Market cap
$46.1M
EPS (diluted)
$-0.8
Shares outstanding
98.1M
Open
Day range
Prev close
Volume
IPO date
May 7, 2015

aTYR PHARMA INC (ATYR) Stock Price

  • Reported a net loss of $74.1M in FY2025.
  • Revenue declined 19% from FY2024 to FY2025.
  • Trading 93% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review aTYR PHARMA INC.

Write a review
Newsroom

News about aTYR PHARMA INC

News & sentiment via Polygon.io

FAQ

aTYR PHARMA INC: frequently asked questions

Is aTYR PHARMA INC an American company?

aTYR PHARMA INC is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is aTYR PHARMA INC headquartered?

aTYR PHARMA INC is headquartered in San Diego, California, United States.

Is aTYR PHARMA INC publicly traded?

Yes — aTYR PHARMA INC is a publicly traded company. Its stock trades under the ticker symbol ATYR on the NASDAQ.

What does aTYR PHARMA INC do?

aTYR PHARMA INC is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →